International Myeloma Working Group guidelines for serum-free light chain analysis in multiple myeloma and related disorders
Angela Dispenzieri(WinnMed), Bart Barlogie(Spanish Head & Neck Cancer Cooperative Group), Pieter Sonneveld(Erasmus MC Cancer Institute), Morie A. Gertz(Mayo Clinic in Arizona), Hermann Einsele(University of Würzburg), Mario Boccadoro(University of Turin), Jesús F. San Miguel(Universidad de Salamanca), Robert A. Kyle(Mayo Clinic in Arizona), Sagar Lonial(Azienda Ospedaliera Citta' della Salute e della Scienza di Torino), Patrizia Tosi(Spanish Head & Neck Cancer Cooperative Group), Michel Attal(Hôpital Purpan), Brian G.M. Durie(Spanish Head & Neck Cancer Cooperative Group), Sundar Jagannath(Mount Sinai Hospital), Heinz Ludwig(Wilhelminen Hospital), María‐Victoria Mateos(Hospital Clínico San Carlos), W. Chen(Beijing Chaoyang Emergency Medical Center), Ingemar Turesson(Spanish Head & Neck Cancer Cooperative Group), Joan Bladé(Spanish Head & Neck Cancer Cooperative Group), Kenneth C. Anderson(Novartis (Switzerland)), Meletios Α. Dimopoulos(National and Kapodistrian University of Athens), Raymond L. Comenzo(Memorial Sloan Kettering Cancer Center), Paul G. Richardson(Dana-Farber Cancer Institute), Orhan Sezer(Charité - Universitätsmedizin Berlin), Antonio Palumbo(Azienda Ospedaliero Universitaria San Giovanni Battista), S. Vincent Rajkumar(Mayo Clinic), Kazuyuki Shimizu(Higashi Osaka City General Hospital), Michèle Cavo(University of Bologna), Giampaolo Merlini(University of Pavia), Roman Hájek(University Hospital Brno), Gareth J. Morgan(NYU Langone Health), D. Joshua(Royal Prince Alfred Hospital), Jean‐Luc Harousseau, R Powles(Parkside Hospital)
Cited by 808
Related Papers
The Global Syndemic of Obesity, Undernutrition, and Climate Change: The Lancet Commission report
|The Lancet|2019|3k
International Staging System for Multiple Myeloma
|Journal of Clinical Oncology|2005|2.9k
An inflammatory cytokine signature predicts COVID-19 severity and survival
|Nature Medicine|2020|2.7k
A Phase 2 Study of Bortezomib in Relapsed, Refractory Myeloma
|New England Journal of Medicine|2003|2.6k